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N-arachidonoyl-L-serine (ARA-S) is an endogenous lipid, chemically related to the endocannabinoid,
N-arachidonoyl ethanolamine (i.e., anandamide) and with similar physiologic and pathophysiologic
functions. Reports indicate that ARA-S possesses vasoactive and neuroprotective properties resembling
those of cannabinoids. However, in contrast to cannabinoids, ARA-S binds weakly to its known classical
receptors, CB1 and CB2, and is therefore considered to be a ‘cannabinoid-like’ substance. The originally
described ARA-S induced-endothelial-dependent vasorelaxation was not abrogated by CB1, CB2 receptor
antagonists or TRPV1 competitive inhibitor. The present report demonstrates that ARA-S enhances the
ﬂuorescence staining of both cannabinoid receptors (CB1 and CB2) in human brain endothelial cells
(HBEC). This reaction is speciﬁc since it was reduced by respective selective receptor antagonist
(SR141716A and SR141728A). ARA-S alone or in the presence of ET-1 was shown to alter the cytoskeleton
(actin). Both ARA-S stimulated phosphorylation of various kinases (MAPK, Akt, JNK and c-JUN) and al-
teration of cytoskeleton are mediated via CB1, CB2 and TRPV1 receptors. The ﬁndings also showed the
involvement of Rho/Rock and PI3/Akt/NO pathways in the ARA-S-induced phosphorylation of kinases
and actin reorganization in HBEC. All of the above mentioned ARA-S-induced effects were reduced by the
treatment with LY294002 (inhibitor of PI3/Akt kinase), except MAPK kinase. In addition, MAPK, JNK,
c-JUN phosphorylation were inhibited by H1152 (inhibitor of Rho/ROCK kinase), except Akt kinase.
Furthermore, PI3/Akt pathway was inhibited by pretreatment with L-NAME (inhibitor of NOS). The
ﬁndings suggest that ARA-S is a modulator of Rho kinase and may play a critical role in the regulation of
its activity and subsequent effects on the cytoskeleton and its role in supporting essential cell functions
like vasodilation, proliferation and movement.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).an open access article under the C
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(R.M. McCarron).1. Introduction
The cerebromicrovascular endothelium derived from human
brain (HBEC) plays a major role in the function of the blood brain
barrier and contributes to vascular tone and blood ﬂow. These cells
are known to possess functional machinery to respond to en-
dogenous and exogenous vasoactive substances as well as other
factors [1]. HBEC also express CB1 and CB2 receptors that respond
to endocannabinoids (e.g., 2-AG, anandamide) which induce Ca2þ
inﬂux and cytoskeleton (i.e., actin and vimentin) reorganization
alone as well as in the presence of ET-1, a known potent vaso-
constrictor [2,3].
N-arachidonoyl-L-serine (ARA-S) is one of many endogenous
lipids found in the brain. This agent is chemically related to the
endocannabinoid N-arachidonoyl ethanolamide and was shown toC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pro-neurogenic [6], and neuroprotective) and a similar physiologic
role as those described for endocannabinoids [4]. However, the
originally described ARA-S induced endothelial-dependent vaso-
dilation observed in vivo in rat abdominal and mesenteric vessels
was not abrogated by CB1, CB2 or TRPV1- antagonists [4]. Thus,
ARA-S has been considered a ‘cannabinoid-like’ substance since, in
contrast to the other cannabinoids, it binds weakly to the known
classical receptors, namely CB1 and CB2 [4]. These studies also
demonstrated that ARA-S stimulated phosphorylation of 44/42
MAPK kinase and Akt protein kinase. The mechanism by which
ARA-S affects endothelial responses (i.e., angiogenesis, wound
healing, inﬂammatory responses, etc.) is variable and involves
different receptors. For example, some studies indicate that ARA-S
effects are mediated by GPR55 receptors [5,7] while other reports
suggest that ARA-S mediated effects do not involve GPR55 [8].
Additional studies to clarify the precise mechanisms of ARA-S-
induced responses will likely indicate differences dependent upon
the model being studied.
In view of the above observations, it was of interest to evaluate
if the cannabinoid-like substance, ARA-S, affected HBEC responses
by examining its effects on cytoskeleton (actins) and signal
transduction pathways.2. Materials and methods
2.1. Chemicals
Arachidonoyl-L-serine (ARA-S) was obtained from Cayman
Chemical Co., Ann Arbor, MI. Endothelin-1 was obtained from
Sigma (Saint Louis, MO). Alexa Fluor Phalloidin 635 was purchased
from Molecular Probes (Eugene, OR). N G-nitro-L-arginine methyl
ester (L-NAME), an inhibitor of nitric oxide synthase (eNOS) and
H1152 ((S)-(þ)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-
hexahydro-1H-1,4-diazepine dihydrochloride), an inhibitor of Rho/
ROCK kinase, were obtained from Calbiochem (La Jolla, CA).
SR141716A, a selective CB1 receptor antagonist, and SR141728A, a
selective CB2 receptor antagonist, were provided by the Research
Triangle Institute, Research Triangle Park, NC. Capsazepine, a
transient receptor potential vanilloid receptor (TRPV-1) antago-
nist, was obtained from Enzo Life Sciences International, Inc.,
Plymouth, PA. LY 2940002 (2-(4-Morpholinyl)-8-phenyl-4H-1-
benzopyran-4-one hydrochloride), an inhibitor of PI3/Akt kinase,
was obtained from EMD Chemical, Inc., Gibbstown, NJ.
2.2. Cell culture and treatment
The technique used for preparing HBEC has been previously
described [9]. Brieﬂy, the cultured microvascular endothelium
were dissociated from microvessels of human brain surgically re-
moved for the treatment of idiopathic epilepsy. For this study,
HBEC (from two cell lines [each derived separately from gray
matter and white matter from different brains], passages 7-15)
were grown to conﬂuence on 1% gelatin-coated 75 cm2 ﬂasks at
37° C in humidiﬁed atmosphere of 5% CO2/air. The purity of the
endothelial cell cultures was 498%, as determined by positive
immunostaining for von Willebrand (factor VIII)-related antigen
and incorporation of acetylated low density lipoprotein, as well as
negative staining for glial cell (GFAP, galactocerebroside, and ED-
2), muscle cell (α-actin), and pericyte (tropomyosin) markers.
L-NAME and H1152 were dissolved in H2O. ARA-S, SR141716A,
SR141728A, LY294002, and capsazepine were prepared in 50%
ethanol. The ﬁnal ethanol concentration in HBEC culture was a
negligible 0.0005% and no ethanol vehicle was added to the con-
trol. Cultured HBEC were incubated with different signaltransduction pathway inhibitors or receptor antagonists alone or
prior to stimulation with ARA-S. Speciﬁcally, cells were incubated
with: 1) 20 μM LY2940022, for 15 min; 2) 10 μM H1152, for
15 min; 3) 100 μM L-NAME (eNOS), for 40 min; or 4) 10 μM cap-
sazepine, for 30 min. HBEC cultures were incubated with
SR141716A or SR141728A for 30 min as previously described [2].
Dose-dependent studies indicated that 1 μM of SR141716A or
SR141728A produced the maximum inhibitory effect on Ca2þ up-
take and cytoskeleton rearrangements induced by en-
docannabinoids [2]. The cells were subsequently exposed to 50 μM
ARA-S for 15 min followed by ET-1 (20 nM) for 1 min; the ARA-S
concentration was determined by dose-dependent pilot studies
evaluating the effect on Ca2þ uptake (to be similar to that of the
cannabinoid effect).
2.3. Western blot analysis
All antibodies used for determination of protein levels were ob-
tained from Cell Signaling Technologies (Danvers, MA). HBEC grown on
60mm petri dishes were washed with HBSS and the feeding medium
was withdrawn and replaced with serum-free medium (M199) over-
night. After treatment with test agents, the cells were lysed in a so-
lution containing 150mM NaCl, 50 mM Tris–HCl, 0.25% sodium
deoxycholate 1mM EGTA, 1 mM NaF, 1 mM Na3VO4, and a cocktail of
proteinase inhibitors (Calbiochem, La Jolla, CA). Protein assays and
Western blot analyses were determined as described previously [3].
Brieﬂy, proteins were separated by SDS-PAGE and transferred to PVDF
membranes. The membranes were blocked in 5% nonfat milk in PBS at
room temperature for 1 h and incubated with antibodies against
phosphorylated Akt (ser473), phosphorylated MAPK (Erk1/2), phos-
phorylated c-JUN, or phosphorylated JNK at 4 °C overnight. The next
day, themembranes werewashed 3 times with a 0.1% Tween 20 in PBS
washing buffer and incubated with HRP-conjugated secondary anti-
body for 45min at room temperature. The membranes were washed
3 times in washing buffer then developed in chemiluminescence re-
agent (SuperSignal West Femto, Thermo Scientiﬁc, Rockford, IL) and
imaged in a Fuji Image analyzer (LAS-3000, FujiﬁlmMedical Systems U.
S.A., Inc. Stamford, CT) to detect the HRP-antibodies complex. Band
density was measured using the software MultiGage (version 2). To
detect total (phosphorylated and non-phosphorylated) proteins, the
membranes were incubated in a stripping buffer (Thermo Scientiﬁc)
for 15min to remove the immune complex and re-probed with total
Akt, MAPK, c-JUN, and JNK antibodies.
2.4. Immunoﬂuorescence staining and confocal microscopy
HBEC were grown on gelatin-coated chambered culture slides
(Thermo Scientiﬁc) for 48 h before treatment with test agents. For
staining of CB1 and CB2 receptors, cells were washed 3 times with
PBS and then ﬁxed in 4% paraformaldehyde for 10 min and per-
meabilized with 0.2% TritonX-100 in PBS for 15 min. After blocking
with 1% bovine serum albumin (BSA) in PBS for 1 h, CB1 and CB2
expression was probed by incubating the samples in goat anti-CB1
(sc-10066, Santa Cruz Biotechnology Inc.; Dallas, TX) or rabbit
anti-CB2 (sc-10073, Santa Cruz) for 1 h at 1:200 ratio in BSA. After
3 washes with PBS, the cells were treated with Alexa Fluor 488-
conjugated anti-goat or anti-rabbit antibody to detect CB1 and CB2
expression, respectively.
To examine cytoskeletal organization, cells grown in monolayers
were washed with PBS, ﬁxed with 4% paraformaldehyde for 10 min,
permeabilized with 0.1% TritonX-100 in PBS for 5 min, and then in-
cubated in BSA for 20 min. To detect F-actin, cells were incubated in
Alexa Fluor-635 phalloidin for 20 min. All stained cells were washed
in PBS prior to mounting with anti-fade mounting medium (Vecta-
shield, Vector Laboratories; Burlingame, CA) containing 4′,6-diami-
dino-2-phenylindole (DAPI) to detect nuclear DNA.
T. Kino et al. / Biochemistry and Biophysics Reports 8 (2016) 254–260256Immunoﬂuorescent staining was detected with a confocal mi-
croscope (Zeiss, LSM 510; Oberkochen, Germany). The cells were
imaged using standard ﬁlter sets and laser lines to acquire double
labeled images. DAPI, CB1/CB2 or actin ﬂuorescence were excited
with 405 nm, 488 nm, and 633 nm laser lines, respectively. The
images were captured using LSM software. Z-stacks were acquired
from the base of the cells (at cover slip) to beyond the top of the
cells to encompass all the cells in the region of interest (ROI).
Fluorescence intensity of actin ﬁbers was estimated using the
software Image J (National Institutes of Health). ROI of equal size
were deﬁned within the cytoplasmic region of phalloidin-stained
non-overlapping cells. Fluorescence intensity was estimated using
an average of 33 ROIs per treatment group.
2.5. Statistical analysis
Statistical analysis of ﬂuorescence and phosphorylation data
was performed using Prism 5 (GraphPad Software Inc., San Diego,
CA), and are presented as the mean7S.E.M. Statistical signiﬁcance
was determined by one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni's multiple comparisons test (Po0.05).3. Results
3.1. General observation
Overall, all the tested responses of HBEC to ARA-S showed
some variability. The degree of stimulation was independent ofFig. 1. Effect of ARA-S on CB1 (A-C) and CB2 (D-F) receptor expression. Cultured HBEC we
with selective antagonists for CB-1 [1 μM SR141716A (SR16)] (C) or CB-2 [1 μM SR14172
labeled with Alexa-488-conjugated antibodies against CB1 (B, C) and CB2 (E, F) recepto
escence uniformly dispersed in the cytoplasm but more condensed in the perinuclear aage, passage and whether the HBEC were derived from gray or
white matter. However, some changes in level of stimulation were
found to correlate with the length of storage of ARA-S preparations
(i.e., fresh ARA-S was more potent than older agent).
3.2. Effects of ARA-S on the CB1 or CB2 cannabinoid receptors
The ﬂuorescence staining of both CB1 and CB2 receptors in the
cytoplasm and nuclei of HBEC were increased by ARA-S treatment
(see Fig. 1). The expression of these receptors was manifested by
granular ﬂuorescence uniformly dispersed in the cytoplasm but
more condensed in the perinuclear areas. In contrast, the nuclear
expression of the ﬂuorescence was punctuated; the granules being
more separated and distinct from each other as compared to their
arrangement in the cytoplasm (Fig. 1B, E). The relative level of
ﬂuorescence induced by ARA-S was reduced or abolished by
treatment with CB1 and CB2 selective antagonists (Fig. 1C, F).
3.3. ARA-S activated various components of signal transduction
pathways
After exposure of HBEC to ARA-S, the MAPK phosphorylation
was increased 2–2.5 fold above the control (Fig. 2A and Table 1A)
and the stimulation of c-JUN was 1.5 fold above the control after
exposure of HBEC to ARA-S (Table 1A). The Akt phosphorylation
was also increased 2–2.5 fold above the control (Fig. 2B and
Table 1A). All the above ﬁndings regarding kinase phosphorylation
were reduced by pretreatment with CB1-, CB2- receptor antago-
nists and competitive inhibitor of TRPV-1; no signiﬁcant differ-
ences were seen between CB1, CB2 and TRPV-1 inhibitory effects)re untreated (A, D) or exposed to 50 μM ARA-S for 15 min alone (B, E) or pre-treated
8A (SR28)] (F) receptors. Confocal analysis of immunoﬂuorescent intensity of HBEC
rs. ARA-S stimulated CB1 (B) and CB2 (E) receptors manifested by granular ﬂuor-
reas. Scale bar¼10 mm.
Fig. 2. (A) Effect of inhibitors on ARA-S -stimulated JNK and MAPK. Bars (means7SE of
pp/np ratio) indicate semi-quantitative analysis of effect of inhibitors on Western blot
analysis of ARA-S -stimulated JNK (hatched) andMAPK (solid black). HBEC were untreated
or pre-treated with ARA-Sþ indicated receptor antagonists as described in the Materials
and Methods section. (B) Effect of inhibitors on ARA-S-stimulated Akt phosphorylation.
Bars (means7SE of pp/np ratio) indicate quantitative analysis of effect of inhibitors on
Western blot analysis of effect of inhibitors on ARA-S-stimulated Akt phosphorylation.
Shown are representative Western blots of at least 7 independent experiments.
Table 1
Characterization of the effects of (A) the antagonists of the CB1, CB2 and vanilloid
receptors and (B) inhibitor of Rho kinase and PI3 on phosphorylation of protein
kinases in ARA-S-stimulated HBEC.
(A)
Control ARA-S ARA-
SþCB1antagonist
ARA-
SþCB2
antagonist
ARA-
Sþvanilloid
antagonist
Akt 1 2.3070.12 1.7270.18 1.7170.19 1.5170.18
MAPK 1 2.3370.16 1.7870.20 1.5770.32 1.5370.21
c-JUN 1 1.4970.07 1.2270.12 0.9770.09 0.7270.18
JNK 1 2.0070.12 1.4770.10 1.3170.18 0.9670.31
(B)
Control ARA-S ARA-
SþLY294002
ARA-SþH1152 ARA-
SþLY294002þ
H1152
Akt 1 2.3270.15 0.3071.00 3.7370.35 0.5770.36
MAPK 1 2.2870.19 1.7370.19 1.1070.10 0.2670.05
c-JUN 1 1.5870.10 0.6970.14 1.1970.10 1.2570.02
JNK 1 2.0270.17 1.1070.10 0.9570.13 0.5770.13
Data indicates density analysis of Western blots. Values (ratio relative to control
value) were analyzed using ANOVA followed by Bonferroni pairwise comparisons.
(A) Treatment with the CB1, CB2 or vanilloid receptor antagonists causes a statisti-
cally signiﬁcant reduction in phosphorylation of all four kinases relative to the ARA-
S- stimulated value (po0.05). (B) ARA-S phosphorylated value vs. ARA-S with
LY294002, H1152, or LY294002þH1152 were statistically different for Akt, MAPK,
c-JUN, and JNK (po0.05 in all cases). LY294002 and H1152 inhibit ARA-S-stimulated
phosphorylation of MAPK, c-JUN and JNK. LY294002 also inhibits the phosphoryla-
tion of Akt, while H1152 enhances the ARA-S-induced phosphorylation of Akt.
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antagonist (Table 1A). Nevertheless, all the studied kinases, except
for MAPK, were almost completely blocked by LY294002, an in-
hibitor of PI3/Akt kinase (Table 1B).
Experiments evaluating the effects of H1152, the inhibitor of
Rho/ROCK pathway, demonstrated that it abrogated the stimula-
tory effect on ARA-S-induced phosphorylation by MAPK, JNK and
c-JUN (Table 1B). Interestingly, in contrast to these observations,
H1152 treatment actually increased the level of ARA-S-induced
phosphorylation of Akt (43-fold increase; Fig. 2B and Table 1B).
This effect of ARA-S was also abrogated by LY294002 (Table 1A). In
addition, the ARA-S stimulated phosphorylation of Akt was re-
duced (50%) with L-NAME (not shown). None of the antagonists or
inhibitors exhibited any effect on kinase phosphorylation in the
absence of ARA-S.
3.4. Effect of ARA-S and ET-1 on cytoskeleton (actin)
The treatment of HBEC with ARA-S led to morphological changes
in the cytoskeleton with ﬁlaments and bundles becoming less dis-
tinct as compared to those in the controls (Fig. 3A and B); the semi-quantitative ﬂuorescence intensity was not signiﬁcantly different
than controls (Table 2). Studies regarding cytoskeletal actin ex-
pression showed that treatment with ET-1 resulted in markedly
thicker actin ﬁlaments and bundles with a considerably higher level
of ﬂuorescence as compared to normal controls (Fig. 3A and C). This
ET-1 induced-actin rearrangement was altered by pretreatment
with ARA-S; it led to rarefaction and decreased thickness as well as
reduced ﬂuorescence intensity (Fig. 3D and Table 2).
These effects of ARA-S on ET-1 treated cells were altered by the
pretreatment with either CB1- or CB2- receptor antagonists
(Fig. 3E and F, respectively). The reduction of ET-1- induced in-
crease in ﬂuorescence by ARA-S was not prevented by pretreat-
ment with CB1-receptor antagonist. However, the structural ap-
pearance of the cytoskeleton was similar to control. Treatment
with CB2-receptor antagonist had a similar effect on the structural
appearance of the cytoskeleton but also reversed the inhibitory
effect of ARA-S on ET-1-induced ﬂuorescence. Pretreatment with
LY294002 prevented the ARA-S effects on ET-1-induced cytoske-
letal effects (Fig. 3G). However, pretreatment with H1152 not only
increased ﬂuorescence but also completely disrupted the appear-
ance of the cytoskeleton observed in cells either untreated or
treated with ET-1 alone or ET-1 with ARA-S (Fig. 3H). The pre-
treatment of the HBEC with L-NAME has a similar effect on the
cytoskeleton as that observed with LY294002 (thickened actin ﬁ-
laments) and reversed the ARA-S-induced inhibitory effect on ET-
1-stimulated cytoskeletal rearrangements (Fig. 3I).4. Discussion
The results of this study demonstrated the involvement of ARA-
S in the protein phosphorylation of a number of signal transduc-
tion pathways (e.g. MAPK, Akt, JNK, and c-JUN) that are often as-
sociated with stress, most of these factors are part of the signal
Fig. 3. Effect of ARA-S and ET-1 on Cytoskeleton (Actin). Cultured HBEC were untreated (A) or exposed to 50 μM ARA-S alone (B), 20 nM ET-1 alone (C), or both ARAS and ET-
1 (D). HBEC treated with both ARA-S and ET-1 were also pre-treated with selective antagonists for CB-1 (E) or CB-2 (F) receptors or LY, inhibitor of Akt kinase (G) H1152,
inhibitor of rho kinase (H) or L-NAME, nitric oxide inhibitor (I). Scale bar¼10 mm.
Table 2
Semi-quantitative analysis of ﬂuorescence intensity of actin ﬁlaments labeled with Alexa-635 phalloidin.
Treatment Absolute ﬂuorescence in-
tensity (arbitrary unit)
Percent change in in-
tensity from ARA-S (%)
P-value for comparison
relative to ARA-S
Percent change in in-
tensity from ET-1 (%)
P-value for comparison
relative to ET-1
Control 15.34 7.4 NS 39.5 Po0.0001
ARA-S 14.29 0.0 – 43.6 Po0.0001
ET-1 25.34 77.3 Po0.0001 0.0 –
ARASþET-1 17.28 20.9 Po0.001 31.8 Po0.0001
ARA-SþET-1þCB1 antagonist 16.27 13.9 NS 35.8 Po0.0001
ARA-SþET-1þCB2 antagonist 18.43 29.0 Po0.0001 27.3 Po0.0001
ARA-SþETþLY294002 18.86 32.0 Po0.0001 25.6 Po0.0001
ARA-SþET-1þ H1152 22.14 54.9 Po0.0001 12.6 NS
ARA-SþETþL-NAME 19.95 39.6 Po0.0001 21.3 Po0.0001
Fluorescence intensities were compared to the ARA-S or ET-1 values using an ANOVA followed by a Bonferroni test for multiple comparisons.
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Fig. 4. Postulated signal transduction pathways of ARA-S modulation of cytoske-
leton via CB1, CB2, TRPV1 receptors. Possible mechanisms of receptor-mediated
activation involve different routes including both Rho/ROCK kinase and PI3/Akt
kinase pathways resulting in cytoskeletal alterations. Inhibition of Rho/ROCK kinase
by H1152 decreases ROCK and ROCK-mediated inhibition of PI3K. Inhibition of PI3/
Akt kinase by LY294002 completely inhibits Akt formation and effects on cytos-
keleton. Akt effects on cytoskeleton are also inhibited by treatment with L-NAME,
inhibitor of e-NOS activity.
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noteworthy that the effects of ARA-S alone, or in combination with
ET-1, were prevented by treatment with CB1, CB2 receptor an-
tagonists, TRPV-1 competitive inhibitor or L-NAME (an inhibitor of
eNOS). The reduction of ARA-S induced-increase of cannabinoid
receptors (ﬂuorescence) by speciﬁc antagonists suggests the CB1
and CB2 mediation of ARA-S-induced effects. The implicated in-
volvement of cannabinoid receptors in these events was further
explored and the precise location of these receptors, whether
present on the surface or internalized inside of the membranes,
was not determined in the present study. However, the inter-
nalization of the receptors does not necessarily rule out the pos-
sibility of involvement in the activation of the signal transduction
pathways since this has been previously reported [10].
These ﬁndings are in contrast to the reported weak binding of
ARA-S to classical cannabinoid (CB1 and CB2) receptors and the de-
scribed ineffectiveness of the cannabinoid receptor antagonists to
affect ARA-S-induced vascular relaxation and angiogenesis [4,5].
Nonetheless, neuroprotection induced by ARA-S was shown to be
mediated by CB2 receptors [8,11] and pro-neurogenic activation by
ARA-S was found to be mediated by both CB1 and CB2 receptors [6].
Such observations could be due to different vascular and/or cellular
derivations, species, and cell types. The discrepancy between func-
tional effects and physical binding associated with a given receptor
(i.e., CB2) may depend upon the structural orientation of a ligand to
the receptor binding site [11]. Although the unstimulated presence of
CB1 and CB2 receptors in the cytoplasm and nuclei of cere-
bromicrovascular endothelial cells were described previously [3], the
present report is the ﬁrst demonstration of the effect of ARA-S on
endothelial cytoplasm and nuclear receptors suggesting that not only
cytoplasmic but also nuclear cannabinoid reactivity in HBEC.
The observed responsiveness of nuclear receptors to a lipid
agent such as ARA-S is in agreement with the ﬁndings regarding
effects of other lipid-like substances and growth factors on nuclear
receptors [12]. The speciﬁc role of lipid activated nuclear receptors
has been extensively studied but is still not fully understood [13].
They are characterized as transcriptional factors activated by so-
luble lipid therefore acting as membrane-permeable ligands reg-
ulating the expression of target genes involved in diverse phy-
siological and pathological responses. Many studies suggest that
fatty acids and their derivatives (eicosanoids, phospholipids,
sphingolipids), including some cannabinoid-like molecules, bind
and activate nuclear receptors [12,14]. Thus, it seems likely that
ARA-S acts as a cannabinoid-like lipid substance that may bind
and activate these receptors. Future studies may clarify additional
aspects of their processes namely the precise location (i.e., outer or
inner surface of membranes) and activation of speciﬁc signal
transduction pathways as well as metabolic pathways [14].
The reorganization of the cytoskeleton induced by ARA-S alone
or in combination with ET-1-stimulation was shown to be mediated
by CB1, CB2, and TRPV-1 receptors, since observed effects were
prevented by their respective receptor antagonists or inhibitors
(Fig. 3 and Table 2). In addition, effects on cytoskeleton also in-
volved Rho/ROCK and PI3/Akt/NO pathways, since the observed
alterations were affected by selective inhibitors of these factors. In
support of these conclusions, our preliminary studies were con-
cerned with the effects of ARA-S on Rho/ROCK kinase and PI3/Akt
kinase activities. In these studies our observations indicated that
ARA-S reduced the activity (30%) of Rho/ROCK kinase in control and
ET-1 stimulated cells; ET-1 was evaluated because it is a known
stimulator of Rho/ROCK kinase. On the other hand, the same
treatment with ARA-S increased (50%) Akt kinase activity. Our
studies are consistent with the ﬁndings that cannabinoid ligands
(stable analogues of anandamide or CB-1 ligands) reduced Rho/
ROCK kinase, stimulated PI3/Akt kinase, reorganized cytoskeleton
(actin) and decreased cell migration [15–17]. These ﬁndings are alsoin agreement with reports that Rho kinase inhibition leads to rapid
activation of PI3/Akt pathway [18].
We previously reported that vasoactive substances such as NO,
2-AG and ET-1 affected the HBEC cytoskeleton (actin and vi-
mentin) [1,3]. It is presently not clear whether the prevention of
ET-1-induced effects on the cytoskeleton reorganization by ARA-S
was directly or indirectly the consequence of GTPase inhibition.
Rho-GTPase has been extensively studied and functions as a cel-
lular cytoskeleton actin stabilizer. In its activated state, RhoA
regulates cellular structure by controlling the dynamic interactions
of microﬁlaments and microtubulin. This event occurs via binding
and activating speciﬁc downstream effector proteins such as Rho
associated coil/coiled kinase (i.e., ROCKI and ROCK II) [19]. Fol-
lowing ROCK activation this molecule becomes a regulator, espe-
cially of actin cytoskeleton remodeling, F-actin stabilization, actin-
network assembly, and actin-membrane linkage [20–22].
The reduction of RhoA activity induced by ARA-S was never
previously studied even though many ARA-S stimulated events or
processes (i.e., vasorelaxation, angiogenesis, ischemia, and trauma)
were demonstrated to be modulated by PI3/Akt pathway [4]. The
ARA-S reorganization of actin ﬁbers observed in normal and ET-1-
stimulated HBEC as shown in the present paper is most likely due
to its effect on RhoA activity since inhibition of RhoA/Rock activity
has been known to affect the changes in cytoskeleton [19,20].
Previous reports indicate that the inhibition of Rho kinase affects
the PI3/Akt signal transduction pathway which, in turn, controls
many biological processes (i.e., cell migration, proliferation, cytoske-
leton reorganization) [18] that are stimulated in many physiological
and pathological conditions (Fig. 4). Many studies have also de-
monstrated that Rho/ROCK activation or reduction of its activity plays
a major role in these processes [17,23]. Indeed, our results (as shown
in Fig. 3) are in agreement with reported inhibitory effects of can-
nabinoid ligands on the cellular cytoskeleton reorganization induced
by ET-1. Furthermore, the pretreatment of the ARA-S induced
T. Kino et al. / Biochemistry and Biophysics Reports 8 (2016) 254–260260reorganization of HBEC cytoskeletonwith speciﬁc inhibitors indicates
that this event is mediated by PI3/Akt induced NO signal transduc-
tion pathway (Fig. 4). Taken together, the ﬁndings suggest that ARA-S
acts as a modulator of Rho/ROCK kinases which are functionally ac-
tive in HBEC. Thus the properties of ARA-S, including potential roles
in vasorelaxation, may have therapeutic value for treatment of vas-
cular diseases.Disclaimer
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